KDR and adrenal cortex carcinoma: Novel targeted therapies such as anti-EGFR such as Cetuximab, and the small molecule inhibitor of VEGFR2, Apatinib, have entered clinical trials and yielded potential clinical benefit in recurrent or metastatic ACC patients (20, 22).